Featured

Checkpoints for the win: neoadjuvant ICB outperforms targeted therapy in melanoma

Neoadjuvant treatment with immunotherapy and/or targeted agents has become standard of care for resectable stage IIIB-D melanoma. However, the optimal treatment regimen and the consequences for long-term survival remain largely unknown. Long et al....

In situ reprogramming of glioma stem cells into dendritic cell-like cells for glioblastoma immunotherapy

Tang, Sun, Yang, et al. reprogrammed glioma stem cells (GSCs) into cDC1-like cells in situ by administering a hydrogel to the post-op tumor cavity for slow and local delivery of CD133-targeting LNPs c...

A structure-informed deep learning framework for modeling TCR-peptide-HLA interactions

Cao et al. developed StriMap – a prediction framework for modeling peptide–HLA presentation and TCR recognition as a coupled process based on physicochemical, sequence-context, and structure-informed...

Peripheral Blood as the Sole Source for Cancer Neoantigen and Reactive T-Cell Discovery

To expand the accessibility of neoantigen-based immunotherapy, Garcia-Garijo et al. integrated circulating tumor DNA (ctDNA) whole-exome sequencing (WES) to identify non-synonymous mutations (NSMs) wi...

Spatially confined IL-12 programs CAR-NK through mTORC1 to coordinate antitumor immune networks

Tarannum et al. engineered mesothelin-targeted CAR-NK cells secreting IL-12 tethered to a collagen-binding A3 domain to spatially restrict IL-12 activity within the collagen I/III-rich TIME. IL-12 and...

See all for this week

Previous Digests

T-RAP – a new tool for predicting TCR-pMHC reactivity

October 7, 2026

Predicting TCR-pMHC reactivity is useful for a variety of immunotherapy research tasks, including identifying relevant neoantigens and developing vaccines. In work recently published in Immunity, Messemaker and Kwee et al. developed a TCR rapid assembly platform (T-RAP) and used...

CD4 takes the lead: IL‑21 synergizes with KRAS inhibition for durable PDAC control

September 30, 2026

Pancreatic ductal adenocarcinoma (PDAC) has proven to be a challenge for immunotherapy treatment. KRAS inhibitors have shown efficacy in PDAC, but acquired resistance is common. In a recent publication in Cell, Qiang, Hoffman, Chun, et al. investigated whether combinations...

PLA2G2D: A new checkpoint lymph node macrophage

September 23, 2026

Tumor-draining lymph nodes (tdLNs) are critical sites for both antitumor immunity and tumor metastasis. To better understand what influences these events, van Krimpen and Huang et al. performed spatial proteogenomics studies on tdLNs from patients with melanoma. In addition...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials